Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Acta Derm Venereol ; 103: adv14153, 2023 Oct 06.
Artículo en Inglés | MEDLINE | ID: mdl-37800349

RESUMEN

The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients' lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.


Asunto(s)
Azetidinas , Dermatitis Atópica , Humanos , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/tratamiento farmacológico , Calidad de Vida , Azetidinas/efectos adversos , Sistema de Registros , Resultado del Tratamiento , Índice de Severidad de la Enfermedad , Método Doble Ciego
2.
Emerg Infect Dis ; 25(12): 2197-2204, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31742503

RESUMEN

Zoonotic transmission of parapoxvirus from animals to humans has been reported; clinical manifestations are skin lesions on the fingers and hands after contact with infected animals. We report a human infection clinically suspected as being ecthyma contagiosum. The patient, a 65-year-old woman, had 3 nodules on her hands. She reported contact with a sheep during the Aïd-el-Fitr festival in France during 2017. We isolated the parapoxvirus orf virus from these nodules by using a nonconventional cell and sequenced the orf genome. We identified a novel orf virus genome and compared it with genomes of other orf viruses. More research is needed on the genus Parapoxvirus to understand worldwide distribution of and infection by orf virus, especially transmission between goats and sheep.


Asunto(s)
Ectima Contagioso/diagnóstico , Ectima Contagioso/virología , Genoma Viral , Virus del Orf/genética , Biopsia , ADN Viral , Ectima Contagioso/epidemiología , Ectima Contagioso/historia , Francia/epidemiología , Historia del Siglo XXI , Humanos , Virus del Orf/clasificación , Virus del Orf/aislamiento & purificación , Virus del Orf/ultraestructura , Filogenia , Reacción en Cadena de la Polimerasa , Vigilancia de la Población , Secuenciación Completa del Genoma
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA